AR and breast cancer: Consistent with these findings, a recent study in patients with ER+/HER2− breast cancer treated with neoadjuvant fulvestrant with or without enza demonstrated that AR inhibition increased expression of immune activation gene sets, including IFNγ signaling, and reduced immunosuppressive myeloid populations (86).